Tolerance induction by "megadose" hematopoietic transplants - Donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture

被引:148
作者
Rachamim, N
Gan, J
Segall, H
Krauthgamer, R
Marcus, H
Berrebi, A
Martelli, M
Reisner, Y [1 ]
机构
[1] Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel
[2] Kaplan Med Ctr, Inst Hematol, Rehovot, Israel
[3] Univ Perugia, I-06100 Perugia, Italy
关键词
D O I
10.1097/00007890-199805270-00017
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Recently, the use of megadoses of CD34(+) hematopoietic progenitors has been reported to abrogate resistance to engraftment, thus overcoming major histocompatibility barriers in bone marrow transplantation in leukemia patients. Methods. The ability of human CD34(+) cells to possess potent tolerizing activity was studied by limiting dilution analysis of cytotoxic T lymphocyte (CTL) precursors (CTL-p) in human peripheral blood lymphocytes after addition of purified CD34(+) cells, Results, The addition of purified human CD34(+) cells to primary mixed lymphocyte culture led to a marked reduction of antiallogeneic CTL-p frequency against stimulator cells of the same origin, compared with the response against cells of third-party origin. The CD34(+) cells caused a marked inhibition of the CTL activity, when added at an equal number with the responder T cells, and they were still present after the mixed lymphocyte culture, which suggests that no significant killing of CD34(+) cells had occurred. The tolerizing activity is abrogated by irradiation and requires cell contact. This pattern of tolerization most closely resembles what has been ascribed to veto cells in other systems. Phenotypic analysis of the purified CD34(+) cells showed that they express MHC class I and class II antigens, but do not express costimulatory molecules of the B7 family, Conclusions. It is possible, that CD34(+) cells in the megadose transplants-perhaps by their inability to provide costimulatory molecules-are actively reducing the frequency of CTL-p directed against their antigens, and thereby help to overcome allogeneic rejection, and enhance their own engraftment.
引用
收藏
页码:1386 / 1393
页数:8
相关论文
共 49 条
[1]   From stem cells to lymphocytes: Biology and transplantation [J].
Aguila, HL ;
Akashi, K ;
Domen, J ;
Gandy, KL ;
Lagasse, E ;
Mebius, RE ;
Morrison, SJ ;
Shizuru, J ;
Strober, S ;
Uchida, N ;
Wright, DE ;
Weissman, IL .
IMMUNOLOGICAL REVIEWS, 1997, 157 :13-40
[2]   CD28-B7 INTERACTIONS IN T-CELL ACTIVATION [J].
ALLISON, JP .
CURRENT OPINION IN IMMUNOLOGY, 1994, 6 (03) :414-419
[3]   SUCCESSFUL ENGRAFTMENT OF T-CELL-DEPLETED HAPLOIDENTICAL 3-LOCI INCOMPATIBLE TRANSPLANTS IN LEUKEMIA PATIENTS BY ADDITION OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR-MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS TO BONE-MARROW INOCULUM [J].
AVERSA, F ;
TABILIO, A ;
TERENZI, A ;
VELARDI, A ;
FALZETTI, F ;
GIANNONI, C ;
IACUCCI, R ;
ZEI, T ;
MARTELLI, MP ;
GAMBELUNGHE, C ;
ROSSETTI, M ;
CAPUTO, P ;
LATINI, P ;
ARISTEI, C ;
RAYMONDI, C ;
REISNER, Y ;
MARTELLI, MF .
BLOOD, 1994, 84 (11) :3948-3955
[4]   MEGADOSE OF T-CELL-DEPLETED BONE-MARROW OVERCOMES MHC BARRIERS IN SUBLETHALLY IRRADIATED MICE [J].
BACHARLUSTIG, E ;
RACHAMIM, N ;
LI, HW ;
LAN, FS ;
REISNER, Y .
NATURE MEDICINE, 1995, 1 (12) :1268-1273
[5]  
BLAZAR BR, 1994, BLOOD, V83, P3815
[6]  
BORDIGNON C, 1989, BLOOD, V74, P2237
[7]   BLOCKADE OF THE CD28 COSTIMULATORY PATHWAY - A MEANS TO INDUCE TOLERANCE [J].
BOUSSIOTIS, VA ;
GRIBBEN, JG ;
FREEMAN, GJ ;
NADLER, LM .
CURRENT OPINION IN IMMUNOLOGY, 1994, 6 (05) :797-807
[8]   POSITIVELY SELECTED AUTOLOGOUS BLOOD CD34+ CELLS AND UNSEPARATED PERIPHERAL-BLOOD PROGENITOR CELLS MEDIATE IDENTICAL HEMATOPOIETIC ENGRAFTMENT AFTER HIGH-DOSE VP16, IFOSFAMIDE, CARBOPLATIN, AND EPIRUBICIN [J].
BRUGGER, W ;
HENSCHLER, R ;
HEIMFELD, S ;
BERENSON, RJ ;
MERTELSMANN, R ;
KANZ, L .
BLOOD, 1994, 84 (05) :1421-1426
[9]  
CLAESSON MH, 1984, J EXP MED, V160, P1702, DOI 10.1084/jem.160.6.1702
[10]  
FINK PJ, 1984, J IMMUNOL, V133, P1775